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background: Renal artery denervation has provided incremental AF suppression after PVI in patients with AF in the setting of drug-resistant 
hypertension, but the potential role of renal denervation in patients with less severe hypertension is unknown. The aim of this prospective 
randomized study was to assess the potential role of renal denervation as an adjunct to pulmonary vein isolation (PVI) in patients with atrial 
fibrillation (AF) and moderate resistant or truly resistant hypertension.
methods: Patients with a history of symptomatic, paroxysmal (P) AF and/or persistent (Pers) AF and moderate resistant hypertension (office BP 
≥140/90 mm Hg and <160/100 mm Hg; n=48), or truly resistant hypertension (≥160/100 mm Hg; n=38) were eligible for the study. Patients were 
randomized to PVI only or PVI with renal artery denervation and were followed-up for one year to assess maintenance of sinus rhythm, and monitor 
changes in blood pressure.
results: At the 12-month follow-up, 26 (63%) of the 41 PVI with renal artery ablation patients were AF-free on no antiarrhythmic drugs vs 16 (41%) 
of the 39 patients in the PVI-only group (p=0.014). In patients with moderate resistant hypertension, the AF recurrence rate was similar after PVI 
only and PVI with renal ablation; 15 (65%) of the 23 PVI with renal artery ablation patients and 11 (52%) of the 21 PVI only patients were AF-free on 
no antiarrhythmic drugs (p=0.19). The results were better in patients with resistant hypertension: 11 (61%) of the 18 PVI with renal artery ablation 
patients vs 5 (28%) of the 18 PVI-only patients were AF-free on no antiarrhythmic drugs (p=0.03).
The superior efficacy of renal ablation was apparent in persistent AF patients (HR 0.39; 95% CI, 0.18 to 0.85; p=0.02), in patients with resistant 
hypertension (HR 0.37; 95% CI, 0.14 to 0.93; p=0.03), and especially in patients with persistent AF and resistant hypertension (HR 0.25; 95% CI, 
0.09 to 0.72; p=0.01).
conclusions: Renal artery denervation can improve the results of PVI, especially in patients with persistent AF and/or truly resistant hypertension.
